Source: Annual Congress 2005 - Borderline indications for surgical treatment of non-small cell lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
L. Spaggiari (Milan, Italy). Locally advanced disease – indications and results of extended resections. Annual Congress 2005 - Borderline indications for surgical treatment of non-small cell lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Source: Eur Respir J 2009; 34: 17-41 Year: 2009 Combined and organ-saving operations in patients with advanced lung cancer after induction chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Combined resection of adjacent organ in NSCLC Source: Annual Congress 2007 - Prognostic factors in lung cancer surgery Year: 2007 SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection Source: Eur Respir J, 56 (5) 2000118; 10.1183/13993003.00118-2020 Year: 2020 Long time survival after resection for multiple primary lung cancers. A population-based study Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Respective indications of chemotherapy, radiotherapy and surgery in limited disease stage small cell lung carcinoma Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Balanced indications for surgery or endobronchial therapy for typical carcinoid tumours Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Early complications after lung resections at patients treated for lung cancer with and without neoadjuvant hemiotheraphy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Surgical treatment of locally recurrent lung cancer Source: Annual Congress 2007 - Recurrence of lung cancer following resection with curative intent Year: 2007 Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Long-term follow-up comparing postoperative chemotherapy or radiotherapy and surgery with surgery alone in resectable nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 131s Year: 2001 Salvage surgery in patients with locally advanced non-small cell lung cancer – outcomes and longtime results Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Comparative evaluation of resectability, postoperative morbidity and mediastinal downstaging after cisplatin-based chemoinduction versus radiochemoinduction for stage III non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 214s Year: 2003 Improved overall survival after early recurrence of lung cancer following the introduction of CT-based follow-up for patients initially treated with curative intent by (chemo)radiotherapy (CRT). Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Treatment of early (stage I/II) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Occult N2 disease after surgical resection for clinical stage I NSCLC: factors affecting survival Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009